Taysha Gene Therapies, Inc. Common Stock(TSHA)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$5.41
52-Week Range
$2.25 – $7.30
YTD
+3.05%
IV Rank (30D)
21.78
Straddle Price
$1.45
P/C Vol Ratio
0.02
Market Cap
$1.6B
Fair Value
-39.6% vs price
Confidence: 13% Alpha Score: 0.22

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.47%
Beta vs SPY1.00
Cost of Equity (CAPM)9.97% (VRP-adj)
WACC9.84%
Volatility Risk Premium+97.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-61.3%
Book / Price11.7%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-1508.6%
Debt / Equity0.23
Quality Score2/6 — normal (10y DCF)
SMA 50$5.73 (Market Anchor value)
SMA 20 / Bollinger Mid$5.85
Bollinger Width / SMA20542.9% (drives anchor stability)
Net Debt$-0.2B
Market Cap$2B
Peers used for multiples: ALKS, AMGN, GILD, RVMD, TGTX, TVTX, TWST, VRTX
Blended Fair Value
$3.26
Current Price
$5.40
Deviation
-39.6%
Forward-Return Rank SHORT gated
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -6.4% -1.83 -0.91 24.5%
42d -7.2% -1.00 -0.91 24.5%
63d -0.6% +1.13 -0.91 24.5%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 24.2× · 5 peers
Peer EV/EBITDA n/a 0% median 28.7× · 6 peers
Peer P/B $6.34 50% median 10.0× · 8 peers
Peer P/S $0.18 50% median 7.9× · 7 peers
Market Anchor (SMA50) $5.73 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-09 · updated 2026-06-09 16:06:15.441000
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$1.6B

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapie…

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -20.17% 6
Feb +6.43% 6
Mar -8.54% 6
Apr +5.89% 6
May +7.07% 6
Jun -6.05% 6
Jul +1.26% 5
Aug +71.11% 5
Sep -9.08% 5
Oct -2.79% 5
Nov +12.70% 5
Dec -6.53% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $5.77
SMA 50: $5.76
SMA 200: $4.78
Current: $5.39
EMA 12: $5.66
EMA 26: $5.78
MACD: -0.1162 | Signal: -0.0562
BEARISH
ADX (14): 18.87
RANGE
+DI: 16.10
−DI: 18.68
Momentum Oscillators
RSI (14): 42.00
NEUTRAL
Stoch %K: 32.00
Stoch %D: 40.20
Williams %R: -73.05
Volume & Volatility
BB Upper: $6.61
BB Lower: $4.94
NEUTRAL
OBV: 188,649,119
Vol SMA 20: 2,186,753
Vol ROC: -58.97%
ATR: $0.38
True Range: $0.37
HV 20: 65.1%
HV 30: 60.1%
HV 60: 84.5%

Data Summary
Data Points: 500
Last Updated: 2026-06-09T16:05:12.139000
Date Range: 2024-06-10T00:00:00 – 2026-06-08T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Options Activity
IV Rank (30D)
21.78
IV Rank (7D)
100
Avg IV
183.0%
Straddle (30D)
$1.45
Straddle (7D)
$1.40
P/C Volume
0.02
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
2.01
Correlation (SPY)
28.0%
0.08
Ann. Volatility
87.7%
SPY Volatility
12.2%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 334,410,825 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

191 filers269,008,117 shares$1.24B value80.44% of float
# Filer Shares Value % of Total % of Float Period
1 RA CAPITAL MANAGEMENT, L.P. 23,555,648 $105.29M 8.50% 7.04% 2026-03-31
2 GOLDMAN SACHS GROUP INC Custodian 22,369,645 $99.99M 8.08% 6.69% 2026-03-31
3 MORGAN STANLEY Custodian 18,078,518 $99.43M 8.03% 5.41% 2025-12-31
4 Avoro Capital Advisors LLC 21,700,000 $97.00M 7.83% 6.49% 2026-03-31
5 BlackRock, Inc. Custodian 18,365,608 $82.09M 6.63% 5.49% 2026-03-31
6 Vestal Point Capital, LP 18,000,000 $80.46M 6.50% 5.38% 2026-03-31
7 VANGUARD GROUP INC Custodian 13,267,805 $72.97M 5.89% 3.97% 2025-12-31
8 FMR LLC Custodian 14,321,255 $64.02M 5.17% 4.28% 2026-03-31
9 RTW INVESTMENTS, LP 13,680,248 $61.15M 4.94% 4.09% 2026-03-31
10 STATE STREET CORP 11,209,078 $50.10M 4.05% 3.35% 2026-03-31
11 Octagon Capital Advisors LP 8,859,911 $39.60M 3.20% 2.65% 2026-03-31
12 Siren, L.L.C. 8,829,913 $39.47M 3.19% 2.64% 2026-03-31
13 Polar Capital Holdings Plc 5,654,340 $25.27M 2.04% 1.69% 2026-03-31
14 GEODE CAPITAL MANAGEMENT, LLC Custodian 5,531,955 $24.73M 2.00% 1.65% 2026-03-31
15 GordonMD Global Investments LP 737,550 $22.22M 1.79% 0.22% 2026-03-31
16 D. E. Shaw & Co., Inc. Custodian 4,427,301 $19.79M 1.60% 1.32% 2026-03-31
17 BAKER BROS. ADVISORS LP 4,004,756 $17.90M 1.45% 1.20% 2026-03-31
18 MILLENNIUM MANAGEMENT LLC Custodian 3,281,820 $14.67M 1.18% 0.98% 2026-03-31
19 Casdin Capital, LLC 3,250,000 $14.53M 1.17% 0.97% 2026-03-31
20 ADAR1 Capital Management, LLC 2,979,429 $13.32M 1.08% 0.89% 2026-03-31
21 HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 2,883,301 $12.89M 1.04% 0.86% 2026-03-31
22 DEERFIELD MANAGEMENT COMPANY, L.P. 2,722,165 $12.17M 0.98% 0.81% 2026-03-31
23 TYBOURNE CAPITAL MANAGEMENT (HK) LTD 3,700,000 $12.10M 0.98% 1.11% 2025-09-30
24 BARCLAYS PLC Custodian 2,812,010 $11.44M 0.92% 0.84% 2026-03-31
25 RICE HALL JAMES & ASSOCIATES, LLC 1,944,671 $8.69M 0.70% 0.58% 2026-03-31
6 filers$1.61M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $526.12K 32.62% 2026-03-31
2 JANE STREET GROUP, LLC Custodian $507.79K 31.49% 2026-03-31
3 CITADEL ADVISORS LLC Custodian $210.98K 13.08% 2026-03-31
4 GROUP ONE TRADING LLC Custodian $185.06K 11.47% 2026-03-31
5 SIMPLEX TRADING, LLC Custodian $116.22K 7.21% 2026-03-31
6 PEAK6 LLC $66.60K 4.13% 2026-03-31
5 filers$353.58K notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $216.79K 61.31% 2026-03-31
2 JANE STREET GROUP, LLC Custodian $60.34K 17.07% 2026-03-31
3 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $49.62K 14.03% 2026-03-31
4 SIMPLEX TRADING, LLC Custodian $22.35K 6.32% 2026-03-31
5 GROUP ONE TRADING LLC Custodian $4.47K 1.26% 2026-03-31
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio7.5
P/S Ratio211.6
EV/EBITDA-10.3
TTM Revenue$0.0B
TTM Net Income$-0.1B
TTM EPS$-0.38
ROE-61.3%
Debt/Equity0.23